Xtant Medical stock: Short interest drops to 143,564 shares for Xtant Medical stock
Published on 10/24/2026 at 02:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSFinancial pressure and calendar
- Short interest stood at 143,564 shares on September 30, 2026, down 46.60 percent from September 15.
- Second-quarter 2026 revenue reached USD 23.0 million versus USD 35.4 million a year earlier.
- Xtant Medical is scheduled to report third-quarter 2026 results on November 10, 2026.
Xtant Medical Holdings (ISIN US98420P3082) saw short interest fall 46.60 percent to 143,564 shares as of September 30, 2026, according to Transcript Daily. The figure compares with 268,742 shares on September 15, while the days-to-cover ratio stood at 0.60 days.
Short interest shifts quickly
The latest short-interest change followed a difficult second quarter. Transcript Daily reported that Xtant Medical posted adjusted and GAAP earnings per share of minus USD 0.07 for the quarter ended June 30, 2026, against a consensus estimate of minus USD 0.02, while revenue reached USD 23.03 million versus USD 24.88 million expected.
The underlying filing gives the broader operating picture. MarketWatch reported that second-quarter 2026 revenue declined to USD 23.0 million from USD 35.4 million in the second quarter of 2025. Gross margin fell to 57.9 percent from 68.6 percent, while the company recorded a net loss of USD 9.4 million compared with net income of USD 3.6 million.
What does the change mean?
The short-interest figure points to a smaller bearish position than two weeks earlier, but the operating figures show why the stock remains closely tied to execution. Xtant Medical reduced its full-year 2026 revenue guidance to USD 99 million to USD 103 million from USD 101 million to USD 105 million, citing weaker biologics revenue and headwinds in its amnio product line, according to MarketWatch.
Three milestones in 2026
On May 13, 2026, Xtant Medical reported first-quarter revenue of USD 20.88 million, according to Earnings Today. On August 11, 2026, the company reported second-quarter revenue of USD 23.03 million against USD 24.88 million expected, also documented by Transcript Daily. On October 16, 2026, the short-interest total was reported at 143,564 shares.
Next reporting date
MarketBeat lists November 10, 2026 as the estimated date for Xtant Medical's third-quarter 2026 results, before the market opens, with an 8:30 a.m. ET conference call.
Small-cap valuation stays sensitive
Xtant Medical had a market capitalization of USD 39.6 million and a 52-week range of USD 0.27 to USD 0.95 as of October 23, 2026. The company is listed on the NYSE American under ticker XTNT and develops regenerative biologics and spinal implant systems for orthopedic and neurological procedures.
The company is valued against a backdrop of lower revenue, narrower short interest and a scheduled results date. Its next report will put the USD 99 million to USD 103 million full-year guidance range back at the center of the investment case.
Market capitalization and the 52-week range are dated October 23, 2026.
The further course of trading is shown by the continuously updated real-time quote of Xtant Medical Holdings stock.
Xtant Medical Holdings key facts
- Company: Xtant Medical Holdings, Inc.
- ISIN: US98420P3082
- Ticker: XTNT
- Primary exchange: NYSE American
- Market capitalization: USD 39.6 million (as of October 23, 2026)
- 52-week range: USD 0.27-USD 0.95 (as of October 23, 2026)
- Sector / Industry: Health Care / Medical Devices
- Next earnings date: November 10, 2026
Market context: Market report S&P 500.
